Axicabtagene ciloleucel (Yescarta)

Abstract

CADTH recommends that Yescarta be reimbursed by public drug plans for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) if certain conditions are met. Yescarta should only be covered to treat adult patients who have grade 1, 2, or 3a FL whose disease has returned following second-line treatment or later lines of treatments. Yescarta should only be reimbursed for patients who have not already received a chimeric antigen receptor (CAR) T-cell therapy and are in relatively good health, and if the cost of Yescarta is reduced. Yescarta should be prescribed and administered by clinicians with expertise in blood cancers in a hospital setting with adequate resources to treat patients and manage side effects.